Rocket Pharmaceuticals, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Rocket Pharmaceuticals, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $152.00K.
- Rocket Pharmaceuticals, Inc. stock issued during period, value, stock options exercised for the quarter ending 2024-09-30 was $176.00K, a 67.71% decline year-over-year.
- Rocket Pharmaceuticals, Inc. stock issued during period, value, stock options exercised for the quarter ending 2024-06-30 was $1.53M, a 740.66% increase year-over-year.
- Rocket Pharmaceuticals, Inc. stock issued during period, value, stock options exercised for the quarter ending 2024-03-31 was $1.18M, a 6.28% increase year-over-year.
- Rocket Pharmaceuticals, Inc. stock issued during period, value, stock options exercised for fiscal 2024 was $3.21M, a 43.93% increase from fiscal 2023.
- Rocket Pharmaceuticals, Inc. stock issued during period, value, stock options exercised for fiscal 2023 was $2.23M, a 253.57% increase from fiscal 2022.
- Rocket Pharmaceuticals, Inc. stock issued during period, value, stock options exercised for fiscal 2022 was $631.00K, a 94.43% decline from fiscal 2021.
- Rocket Pharmaceuticals, Inc. stock issued during period, value, stock options exercised for fiscal 2021 was $11.33M, a 342.81% increase from fiscal 2020.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $152.00K 10-Q · filed 2026-08-10 | |
| 2024-12-31 | $3.21M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $176.00K 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $1.53M 10-Q · filed 2025-11-06 | |
| 2024-03-31 | $1.18M 10-Q · filed 2025-11-06 | |
| 2023-12-31 | $2.23M 10-K · filed 2025-02-27 | |
| 2023-09-30 | $545.00K 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $182.00K 10-Q · filed 2024-11-07 | |
| 2023-03-31 | $1.11M 10-Q · filed 2024-11-07 | |
| 2022-12-31 | $631.00K 10-K · filed 2025-02-27 | |
| 2022-09-30 | $229.00K 10-Q · filed 2023-11-07 | |
| 2022-06-30 | $3.00K 10-Q · filed 2023-11-07 | |
| 2022-03-31 | $76.00K 10-Q · filed 2023-11-07 | |
| 2021-12-31 | $11.33M 10-K · filed 2024-02-27 | |
| 2021-09-30 | $284.00K 10-Q · filed 2022-11-04 | |
| 2021-06-30 | $1.11M 10-Q · filed 2022-11-04 | |
| 2021-03-31 | $8.79M 10-Q · filed 2022-11-04 | |
| 2020-12-31 | $2.56M 10-K · filed 2023-02-28 | |
| 2020-09-30 | $587.00K 10-Q · filed 2021-11-05 | |
| 2020-06-30 | $290.00K 10-Q · filed 2021-11-05 | |
| 2020-03-31 | $0.00 10-Q · filed 2021-11-05 | |
| 2019-12-31 | $31.00K 10-K · filed 2022-02-28 | |
| 2019-09-30 | $31.00K 10-Q · filed 2020-11-06 | $30.00K derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $0.00 10-Q · filed 2020-11-06 | $148.00K derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $0.00 10-Q · filed 2020-11-06 | $148.00K derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $148.00K 10-K · filed 2021-03-01 |
| 2018-09-30 | $149.00K 10-Q · filed 2019-11-08 | |
| 2018-06-30 | $0.00 10-Q · filed 2019-11-08 | |
| 2016-12-31 | $191.00K 10-K · filed 2018-03-07 | |
| 2015-12-31 | $43.00K 10-K · filed 2017-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |